StreetInsider.com News Articles

Form 4 Adaptive Biotechnologies For: Jun 11 Filed by: BOBULSKY SUSAN

Mon, 15 Jun 2026 19:13:00 -0400

si-local-file:///var/storage/secattach/20260615/26649013.html

Form 4 Adaptive Biotechnologies For: Jun 11 Filed by: BOBULSKY SUSAN

Mon, 15 Jun 2026 19:13:00 -0400

si-local-file:///var/storage/secattach/20260615/26649013.html

Form 144 Adaptive Biotechnologies Filed by: ROBINS HARLAN S

Mon, 15 Jun 2026 18:10:00 -0400

si-local-file:///var/storage/secattach/20260615/26648878.html

Form 144 Adaptive Biotechnologies Filed by: ROBINS HARLAN S

Mon, 15 Jun 2026 18:10:00 -0400

si-local-file:///var/storage/secattach/20260615/26648878.html

Form 8-K Adaptive Biotechnologies For: Jun 15

Mon, 15 Jun 2026 16:16:00 -0400

si-local-file:///var/storage/secattach/20260615/26647592.html

Form 8-K Adaptive Biotechnologies For: Jun 15

Mon, 15 Jun 2026 16:16:00 -0400

si-local-file:///var/storage/secattach/20260615/26647592.html

Adaptive Biotechnologies (ADPT) to Separate Its MRD and Immune Medicine Businesses

Mon, 15 Jun 2026 16:10:34 -0400

Adaptive Biotechnologies Corporation (Nasdaq: ADPT), a commercial-stage biotechnology company focused on translating the genetics of the adaptive immune system into clinical products to diagnose and treat disease, today announced its intention to pursue a separation of its Minimal Residual Disease (MRD) and Immune Medicine businesses. The company is evaluating strategic and structural alternatives for Immune Medicine to support its growth strategy, capital needs, and value creation opportunities outside of Adaptive, and expects to identify its preferred path to separation by year-end 2026.

Since establishing MRD and Immune Medicine as separate operating segments under Adaptive in 2024, both businesses have continued to

Adaptive Biotechnologies (ADPT) to Separate Its MRD and Immune Medicine Businesses

Mon, 15 Jun 2026 16:10:34 -0400

Since establishing MRD and Immune Medicine as separate operating segments under Adaptive in 2024, both businesses have continued to

Adaptive Biotechnologies (ADPT) to Separate Its MRD and Immune Medicine Businesses

Mon, 15 Jun 2026 16:10:34 -0400

Since establishing MRD and Immune Medicine as separate operating segments under Adaptive in 2024, both businesses have continued to

Adaptive Biotechnologies Announces Plan to Separate Its MRD and Immune Medicine Businesses

Mon, 15 Jun 2026 16:10:00 -0400

MRD has scaled into a profitable, category-leading MRD diagnostics business, while Immune Medicine has built a differentiated discovery platform powered by proprietary immune data and AI

SEATTLE, June 15, 2026 (GLOBE NEWSWIRE) -- Adaptive Biotechnologies Corporation (Nasdaq: ADPT), a commercial-stage biotechnology company focused on translating the genetics of the adaptive immune system into clinical products to diagnose and treat disease, today announced its intention to pursue a separation of its Minimal Residual Disease (MRD) and Immune Medicine businesses. The company is evaluating strategic and structural alternatives for Immune Medicine to support its growth strategy, capital needs, and value creation

Adaptive Biotechnologies Announces Plan to Separate Its MRD and Immune Medicine Businesses

Mon, 15 Jun 2026 16:10:00 -0400

MRD has scaled into a profitable, category-leading MRD diagnostics business, while Immune Medicine has built a differentiated discovery platform powered by proprietary immune data and AI

Adaptive Biotechnologies (ADPT) to offer $250 million in convertible senior notes due 2031

Mon, 15 Jun 2026 16:07:33 -0400

Adaptive Biotechnologies Corporation (“Adaptive Biotechnologies”) (Nasdaq: ADPT) today announced its intention to offer, subject to market and other conditions, $250 million aggregate principal amount of convertible senior notes due 2031 (the “notes”) in a private offering to persons reasonably believed to be qualified institutional buyers pursuant to Rule 144A under the Securities Act of 1933, as amended (the “Securities Act”). Adaptive Biotechnologies also expects to grant the initial purchasers of the notes an option to purchase, for settlement within a period of 13 days from, and including, the date the notes are first issued, up to an additional $37.5 million

Adaptive Biotechnologies Corporation Announces Proposed Convertible Senior Notes Offering

Mon, 15 Jun 2026 16:05:00 -0400

Proceeds expected to be deployed to repay the OrbiMed Purchase Agreement to enhance financial flexibility
Additional proceeds used to pay for the capped call with a premium of at least 75% and to repurchase up to $25 million of common stock to reduce potential dilution
Remaining capital to be used for general corporate purposes and opportunistic initiatives in the MRD business

SEATTLE, June 15, 2026 (GLOBE NEWSWIRE) -- Adaptive Biotechnologies Corporation (“Adaptive Biotechnologies”) (Nasdaq: ADPT) today announced its intention to offer, subject to market and other conditions, $250 million aggregate principal amount of convertible senior

Adaptive Biotechnologies Corporation Announces Proposed Convertible Senior Notes Offering

Mon, 15 Jun 2026 16:05:00 -0400

Proceeds expected to be deployed to repay the OrbiMed Purchase Agreement to enhance financial flexibility
Additional proceeds used to pay for the capped call with a premium of at least 75% and to repurchase up to $25 million of common stock to reduce potential dilution
Remaining capital to be used for general corporate purposes and opportunistic initiatives in the MRD business

Adaptive Biotechnologies Corporation Announces Proposed Convertible Senior Notes Offering

Mon, 15 Jun 2026 16:05:00 -0400

Proceeds expected to be deployed to repay the OrbiMed Purchase Agreement to enhance financial flexibility
Additional proceeds used to pay for the capped call with a premium of at least 75% and to repurchase up to $25 million of common stock to reduce potential dilution
Remaining capital to be used for general corporate purposes and opportunistic initiatives in the MRD business

Adaptive Biotechnologies Corporation Announces Proposed Convertible Senior Notes Offering

Mon, 15 Jun 2026 16:05:00 -0400

Proceeds expected to be deployed to repay the OrbiMed Purchase Agreement to enhance financial flexibility
Additional proceeds used to pay for the capped call with a premium of at least 75% and to repurchase up to $25 million of common stock to reduce potential dilution
Remaining capital to be used for general corporate purposes and opportunistic initiatives in the MRD business

Form 144 Adaptive Biotechnologies Filed by: BOBULSKY SUSAN

Thu, 11 Jun 2026 16:38:00 -0400

si-local-file:///var/storage/secattach/20260611/26636340.html

Form 144 Adaptive Biotechnologies Filed by: BOBULSKY SUSAN

Thu, 11 Jun 2026 16:38:00 -0400

si-local-file:///var/storage/secattach/20260611/26636340.html

Form 8-K Adaptive Biotechnologies For: Jun 05

Tue, 09 Jun 2026 16:31:00 -0400

si-local-file:///var/storage/secattach/20260609/26624170.html

Form 8-K Adaptive Biotechnologies For: Jun 05

Tue, 09 Jun 2026 16:31:00 -0400

si-local-file:///var/storage/secattach/20260609/26624170.html

Form 4 Adaptive Biotechnologies For: Jun 04 Filed by: LO FRANCIS

Mon, 08 Jun 2026 20:29:00 -0400

si-local-file:///var/storage/secattach/20260608/26618843.html

Form 4 Adaptive Biotechnologies For: Jun 04 Filed by: LO FRANCIS

Mon, 08 Jun 2026 20:29:00 -0400

si-local-file:///var/storage/secattach/20260608/26618843.html

Form 4 Adaptive Biotechnologies For: Jun 04 Filed by: BOBULSKY SUSAN

Mon, 08 Jun 2026 20:27:00 -0400

si-local-file:///var/storage/secattach/20260608/26618841.html

Form 4 Adaptive Biotechnologies For: Jun 04 Filed by: BOBULSKY SUSAN

Mon, 08 Jun 2026 20:27:00 -0400

si-local-file:///var/storage/secattach/20260608/26618841.html

Form 144 Adaptive Biotechnologies Filed by: BOBULSKY SUSAN

Thu, 04 Jun 2026 16:35:00 -0400

si-local-file:///var/storage/secattach/20260604/26606307.html